<DOC>
	<DOCNO>NCT00335543</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving chemotherapy together radiation therapy surgery may make tumor small reduce amount normal tissue need remove . Giving chemotherapy surgery may kill tumor cell remain surgery . It yet know whether give chemotherapy together radiation therapy surgery effective surgery alone treat pancreatic cancer . PURPOSE : This randomized phase II trial study well give gemcitabine cisplatin together radiation therapy surgery work compare surgery alone treat patient localize pancreatic cancer remove surgery .</brief_summary>
	<brief_title>Gemcitabine , Cisplatin , Radiation Therapy Followed By Surgery Surgery Alone Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether neoadjuvant chemoradiotherapy comprise gemcitabine hydrochloride , cisplatin , radiotherapy good immediate surgery , term median survival , patient locally resectable adenocarcinoma pancreatic head . Secondary - Compare 3-year survival rate patient treat regimen . - Compare R0 resection rate patient . - Compare rate medium high toxicity event patient . - Compare rate complete incomplete remission tumor measure radiographic imaging study . - Compare rate different regression grading resect tumor specimen . - Compare quality life patient . OUTLINE : This prospective , randomize , control , open-label , multicenter study . Patients stratify accord participate center stag laparoscopy ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive gemcitabine hydrochloride IV 30 minute cisplatin IV 1 hour day 1 , 8 , 22 , 29 . Patients also undergo radiotherapy tumor surround lymph node 5 day week 5 week follow 3 dos radiotherapy directly tumor . Approximately 6 week finish chemoradiotherapy , patient evidence disease progression undergo surgery remove tumor . - Arm II : Patients undergo surgery remove tumor . After surgery , patient receive adjuvant chemotherapy comprise gemcitabine hydrochloride IV 30 minute day 1 , 8 , 15 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Quality life assess baseline , end chemotherapy surgery ( arm I ) , 6 week , 6 month , 12 month , 24 month surgery . After completion study treatment , patient follow every 3 month 2 year 3 year . PROJECTED ACCRUAL : A total 254 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma pancreatic head No tumor body tail , define tumor lying leave border superior mesenteric vein leave border aorta and/or leave border aorta hilum spleen Locally resectable disease CT scan Major vessel ( e.g. , portal vein , confluence mesenteric splenic vein , superior mesenteric artery , celiac trunk , splenic artery , hepatic artery , superior mesenteric vein ) maximally enclose ≤ 180° tumor No infiltration extrapancreatic organ except duodenum No carcinoma ampulla Vater No metastasis No peritoneal carcinoma PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Creatinine clearance &gt; 70 mL/min Creatinine &lt; 1.5 mg/dL Platelet count &gt; 100,000/mm³ No liver cirrhosis Not pregnant No New York Heart Association class III IV heart disease No respiratory insufficiency No grade III IV cardiac arrhythmia No pathology EKG No severe cardiopulmonary disease No HIV infection No disease render patient unsuitable one treatment option No malignancy except nonmelanoma skin cancer , carcinoma situ cervix , cancer patient treat surgery complete remission ≥ 10 year PRIOR CONCURRENT THERAPY : At least 3 month since prior participation another clinical trial No prior concurrent treatment carcinoma pancreas</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
</DOC>